NVIDIA
NVDA
Super Micro Computer
SMCI
Tesla
TSLA
4
Palantir
PLTR
5
Alibaba
BABA
US Stock MarketDetailed Quotes
RPRX Royalty Pharma
- 33.590
- -0.100-0.30%
Trading Feb 26 12:35 ET
14.56BMarket Cap17.59P/E (TTM)
33.870High33.380Low648.03KVolume33.530Open33.690Pre Close21.84MTurnover0.17%Turnover Ratio17.59P/E (Static)433.32MShares34.20052wk High2.10P/B13.03BFloat Cap23.89152wk Low0.84Dividend TTM387.82MShs Float50.882Historical High2.50%Div YieldTTM1.45%Amplitude23.891Historical Low33.706Avg Price1Lot Size
Royalty Pharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -3.86%2.26B | -0.41%593.64M | 5.29%564.69M | -0.17%537.27M | -16.96%567.98M | 5.24%2.35B | 5.36%596.07M | -6.48%536.31M | 0.42%538.2M | 21.69%683.97M |
| Operating revenue | -3.86%2.26B | -0.41%593.64M | 5.29%564.69M | -0.17%537.27M | -16.96%567.98M | 5.24%2.35B | 5.36%596.07M | -6.48%536.31M | 0.42%538.2M | 21.69%683.97M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 12.61%971.13M | 1,479.41%232.13M | -144.27%-170.38M | -7.51%267.64M | 213.05%641.75M | -34.38%862.4M | -103.89%-16.83M | 0.95%384.87M | 82.95%289.36M | -40.12%205M |
| Selling and administrative expenses | -5.24%236.67M | 14.20%67.59M | -0.90%56.72M | 14.85%54.71M | -32.72%57.65M | 9.87%249.75M | -19.18%59.19M | 12.91%57.23M | -8.12%47.63M | 66.27%85.7M |
| -General and administrative expense | -5.24%236.67M | 14.20%67.59M | -0.90%56.72M | 14.85%54.71M | -32.72%57.65M | 9.87%249.75M | -19.18%59.19M | 12.91%57.23M | -8.12%47.63M | 66.27%85.7M |
| Research and development costs | -96.15%2M | 0.00%500K | -99.01%500K | 0.00%500K | 0.00%500K | -70.64%52M | -99.01%500K | 98.04%50.5M | -17.49%500K | -99.50%500K |
| Depreciation amortization depletion | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Depreciation and amortization | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other operating expenses | 30.64%732.46M | 314.39%164.04M | -182.13%-227.6M | -11.94%212.43M | 391.23%583.6M | -38.00%560.66M | -124.77%-76.51M | -9.15%277.14M | 128.19%241.23M | -35.65%118.8M |
| Operating profit | -13.38%1.29B | -41.02%361.51M | 385.38%735.07M | 8.35%269.63M | -115.40%-73.77M | 61.68%1.49B | 360.23%612.9M | -21.21%151.44M | -34.13%248.84M | 117.99%478.97M |
| Net non-operating interest income expense | -55.07%-178.17M | -39.18%-56.72M | -116.83%-49M | -67.32%-35.63M | -21.71%-36.82M | -4.81%-114.9M | -1,213.83%-40.76M | 31.41%-22.6M | 40.92%-21.3M | 19.41%-30.25M |
| Non-operating interest income | -34.51%47.34M | 39.03%9.04M | -25.29%17.51M | -47.84%13.38M | -55.59%7.42M | -7.72%72.29M | -85.18%6.5M | 66.99%23.44M | 134.94%25.65M | 75.28%16.7M |
| Non-operating interest expense | 20.47%225.51M | 39.16%65.76M | 44.47%66.51M | 4.40%49.01M | -5.79%44.23M | -0.41%187.19M | 0.64%47.26M | -2.01%46.03M | -0.04%46.95M | -0.24%46.95M |
| Other net income (expense) | -32.93%216.54M | -79.68%29.56M | 1,877.22%120.28M | -132.01%-39.62M | 76.12%106.32M | 155.36%322.83M | 119.65%145.45M | -111.07%-6.77M | -17.39%123.79M | 211.58%60.37M |
| Gain on sale of security | -40.30%188.46M | -99.94%100K | 69,172.67%111.53M | -138.33%-47.32M | 334.52%124.15M | 460.20%315.69M | 240.63%163.49M | -99.79%161K | -17.77%123.47M | 154.17%28.57M |
| Earnings from equity interest | 2.52%29.61M | 11,709.70%31.65M | 299.29%10.41M | 321.17%1.7M | -140.89%-14.15M | 421.88%28.88M | 103.91%268K | -60.63%-5.22M | -204.48%-770K | 8,616.88%34.61M |
| Special income (charges) | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Write off | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 92.97%-1.53M | 88.04%-2.19M | 3.10%-1.65M | 449.95%6M | -31.00%-3.69M | -47.32%-21.74M | -1,471.50%-18.31M | 84.19%-1.71M | 205.41%1.09M | -60.10%-2.81M |
| Income before tax | -21.72%1.33B | -53.41%334.35M | 560.53%806.36M | -44.67%194.38M | -100.84%-4.27M | 638.96%1.7B | 217.63%717.59M | -44.61%122.08M | -28.53%351.34M | 297.47%509.09M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -21.72%1.33B | -53.41%334.35M | 560.53%806.36M | -44.67%194.38M | -100.84%-4.27M | 638.96%1.7B | 217.63%717.59M | -44.61%122.08M | -28.53%351.34M | 297.47%509.09M |
| Net income continuous Operations | -21.72%1.33B | -53.41%334.35M | 560.53%806.36M | -44.67%194.38M | -100.84%-4.27M | 638.96%1.7B | 217.63%717.59M | -44.61%122.08M | -28.53%351.34M | 297.47%509.09M |
| Minority interest income | -16.53%471.83M | -43.50%126.14M | 425.13%262.37M | -25.33%92.37M | -105.38%-9.05M | 201.90%565.25M | 245.02%223.25M | -35.75%49.96M | -33.88%123.71M | 120.56%168.33M |
| Net income attributable to the parent company | -24.31%858.98M | -57.88%208.21M | 654.34%543.99M | -55.19%102M | -98.60%4.78M | 2,549.50%1.13B | 208.39%494.34M | -49.45%72.11M | -25.25%227.63M | 558.32%340.76M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -24.31%858.98M | -57.88%208.21M | 654.34%543.99M | -55.19%102M | -98.60%4.78M | 2,549.50%1.13B | 208.39%494.34M | -49.45%72.11M | -25.25%227.63M | 558.32%340.76M |
| Basic earnings per share | -24.41%1.92 | -57.98%0.4664 | 662.50%1.22 | -54.90%0.23 | -98.68%0.01 | 2,440.00%2.54 | 206.73%1.11 | -50.00%0.16 | -27.14%0.51 | 533.33%0.76 |
| Diluted earnings per share | -24.51%1.91 | -67.90%0.3531 | 656.25%1.21 | -54.00%0.23 | -98.68%0.01 | 2,430.00%2.53 | 174.96%1.1 | -50.00%0.16 | -28.57%0.5 | 533.33%0.76 |
| Dividend per share | 5.00%0.84 | 5.00%0.21 | 5.00%0.21 | 5.00%0.21 | 5.00%0.21 | 5.26%0.8 | 5.26%0.2 | 5.26%0.2 | 5.26%0.2 | 5.26%0.2 |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |